Publications, Pharmaceutical

Investigating Breathable HPV-L2 Dry Powder Vaccine using GLA as Amphiphilic Lubricant and Immune-adjuvant

Dry powder respirable vaccines combine the advantage of high patient acceptability with a lack of any requirement for cold chain storage, an important logistical and economic benefit.

This paper describes a proof-of-concept validation of a dry powder human papillomavirus (HPV) respirable vaccine developed using a particle engineering approach. A key characteristic of the developed formulation is the application of glucopyranosyl lipid A (GLA) to the surface of vaccine particles to simultaneously improve aerosolization performance and recognition by the lung immune cells. Extensive in vitro characterization of the resulting formulation was carried out along with in vivo tests to determine lung deposition behavior, following intratracheal administration to mice. A subsequent short-term immunization study provided evidence of an immune response comparable to that achieved via subcutaneous delivery.

Download Publication
10 Dec 2021

Learn more about Aptar Pharma Expertise
in Pulmonary Drug Delivery

Find Out More

This Might Also Be of Interest

24 Apr 2024

Advancing OINDP Clinical Trials with Speed and Efficiency: Strategies for Success

Publications, Pharmaceutical, Innovation & Insights, Market Insights, Product Solutions

Read More
24 Apr 2024

Exploring Nasal Casts in Nasal Drug Development

Publications, Pharmaceutical, Innovation & Insights, Market Insights, Product Solutions

Read More
22 Apr 2024

Navigating the Shift to more sustainable Low GWP propellants in pMDIs

Publications, Pharmaceutical, Sustainability, Brand Differentiation, Market Insights, Product Solutions

Read More
26 Mar 2024

Optimizing Preclinical Studies for Intranasal and Pulmonary Programs

Webinars, Pharmaceutical, Innovation & Insights, Device Innovations, Market Insights, Product Solutions

Read More
1 2 3 19
Back To Top